3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
106
Carcinoma, Non-Small-Cell Lung
34
Carcinoma, Renal Cell
23
Prostatic Neoplasms
17
Neoplasms
15
Brain Neoplasms
15
Neoplasm Metastasis
14
Lung Neoplasms
12
Breast Neoplasms
11
Uveal Melanoma
10
Pancreatic Neoplasms
10
Sarcoma
9
Small Cell Lung Carcinoma
7
Urinary Bladder Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
6
Kidney Neoplasms
6
Diabetes Mellitus, Insulin-Dependent, 12
6
Carcinoma, Transitional Cell
6
Carcinoma, Hepatocellular
6
Skin Neoplasms
5
Ovarian Neoplasms
5
Histiocytoma, Malignant Fibrous
5
Colorectal Neoplasms
5
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
4
Recurrence
4
Neuroendocrine Tumors
4
Mesothelioma
4
Glioblastoma
4
Colonic Neoplasms
4
Interventions
cabazitaxel
3
Trastuzumab
3
Cyclophosphamide
2
Cetuximab
2
Carboplatin
2
Aspirin
2
ribociclib
1
pertuzumab
1
eribulin
1
Thiotepa
1
Taxes
1
Stem Cell Transplantation
1
Propofol
1
Positron Emission Tomography Computed Tomography
1
Paclitaxel
1
Neoadjuvant Therapy
1
Liquid Biopsy
1
Letrozole
1
Ipilimumab
1
Histamine H2 Antagonists
1
Histamine Antagonists
1
Gemcitabine
1
Fulvestrant
1
Epirubicin
1
Docetaxel
1
Denosumab
1
Circulating Tumor DNA
1
Cell-Free Nucleic Acids
1
CA-72-4 antigen
1
CA-19-9 Antigen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplastic Cells, Circulating
×
Ipilimumab
×
Clear all
NCT01565837
2016-02-01
SART
Comprehensive Cancer Centers of Nevada
Phase 2
Unknown
50 enrolled